Drug Trial Radar · NCT06164587
Evaluation of Kamuvudine-8 in Subjects With Geographic Atrophy
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Apr 18, 2024
Primary completion
May 15, 2026
Study completion May 15, 2026
Sponsor
- Lead sponsor
- Inflammasome TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This interventional study is a single-center, open label, 26-week study, designed to evaluate the safety and treatment efficacy of K8 in patients with geographic atrophy (GA) due to age-related macular degeneration (AMD). Up to 5 subjects will receive study medication. Study treatment will be administered by intravitreal injections. Number of participants has been expanded to 30. Participants will have 7 scheduled visits - Screening with baseline (injection), safety visit 2 days after injection, week 4, week 13 (injection), safety visit 2 days after injection, week 17, week 26. Exams will look for continuous changes in visual acuity, change in area of geographic atrophy lesions in diagnostic imaging, response measured by multifocal electroretinogram, change in reading speed, and change in microperimetry response.
Conditions
- Geographic Atrophy
- Age-Related Macular Degeneration
Interventions
K8Drug
sustained released bio-erodible intravitreal implants
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Within the study period (of 26 weeks)
- Mean change in best-corrected visual acuity (BCVA)Time frame: At baseline visit, week 13 visit, and week 26 visit
- Mean change in low-luminance best-corrected visual acuity (ll-BCVA)Time frame: At baseline visit, week 13 visit, and week 26 visit
- Change in size of geographic atrophy (GA) on fundus autofluorescence (FAF)Time frame: At baseline visit, week 13 visit, and week 26 visit
- change in size of geographic atrophy (GA) on optical coherence tomography (OCT)Time frame: At baseline visit, week 13 visit, and week 26 visit
- change in size of geographic atrophy (GA) on fluorescein angiogram (FA)Time frame: At baseline visit, week 13 visit, and week 26 visit
- Change in multifocal electroretinograms (mfERG) responseTime frame: At baseline visit, week 13 visit, and week 26 visit
- Change in microperimetry responseTime frame: At baseline visit, week 13 visit, and week 26 visit
- Change in reading speedTime frame: At baseline visit, week 13 visit, and week 26 visit
- Discontinued subjectsTime frame: This will be done at every scheduled visit and any unscheduled visit, as well as when reported by participants (for 26 weeks)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Loma Linda University
Loma Linda, California
University of Kentucky Advanced Eye Care
Lexington, Kentucky
The Maine Eye Center
Portland, Maine
Oregon Eye Consultants, Cascade Medical Research
Eugene, Oregon
Hilton Head Retina Institute
Hilton Head, South Carolina
Ophthalmology LTD
Sioux Falls, South Dakota
Southeastern Retina Associates
Hixson, Tennessee
Southeastern Retina Associates
Bristol, Virginia
Vistar Eye Center
Roanoke, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.